Selective estrogen receptor β agonist

This technology is a class of small molecule conjugates that exhibit selective estrogen receptor β agonism, promoting anti-aging benefits in metabolism and skin recovery.

Unmet Need: Estrogen receptor β-specific agonist for greater activation

Estrogen is a hormone that has been shown to promote anti-aging benefits in metabolism and skin recovery. Current methods that provide greater activation of the estrogen receptor (ER) are mostly non-receptor specific. ER β-specific agonists are not delivered efficiently into the body due to either polarity or degradation. Methods that activate ERα increase the risk of cancer and toxicity. There is thus a need for an efficient ER β -specific agonist that promotes greater activation.

The Technology: Small molecule conjugates with selective estrogen receptor β agonism

This technology describes a unique class of estrogen receptor (ER) β-selective agonist conjugates that can be absorbed through the skin. This technology is rapidly hydrolyzed upon absorption, which can limit the risk of chemical toxicity. The selective conjugates were shown to alleviate insulin resistance, adipose degeneration, and muscle frailty and promote skin healing upon injury in a murine model. This technology can not only confer anti-aging benefits but also provide treatments for metabolic diseases such as obesity and diabetes.

This model has been tested in murine models.

Applications:

  • Metabolic disease treatment
  • Prevention or treatment of aging-associated complications
  • Healing of skin injuries
  • Hair growth
  • Therapeutic delivery mechanism

Advantages:

  • Limits chemical toxicity
  • Lowers risk of cancer
  • Selectively targets estrogen receptor β
  • Rapidly hydrolyzes
  • Efficiently absorbs into the skin

Lead Inventor:

Li Qiang, Ph.D.

Patent Information:

Patent Pending

Related Publications:

Tech Ventures Reference: